Skip to main content
. Author manuscript; available in PMC: 2013 Sep 10.
Published in final edited form as: Biomacromolecules. 2012 Aug 21;13(9):2645–2654. doi: 10.1021/bm300472y

Figure 9. dpA3 Encapsulated PAX reduces HeLa cell viability.

Figure 9

(a) At a constant concentration of dpA3 (125 μM), increasing concentrations of PAX were encapsulated using thin film hydration. Analytical Reverse Phase HPLC was used to quantify PAX, and the area under the curve (AUC) for the appropriate peak is presented. This trace shows saturable encapsulation above 50 μM PAX at dpA3:PAX ratio of 1:0.8; therefore, dpA3:PAX nanoparticles approach ~29% by mass drug loading. (b) A cytotoxity assay was used to determine if dpA3 was able to deliver PAX to cells using the MTS assay. There is no difference in efficacy of encapsulated PAX compared to free PAX solubilized in DMSO.